Drug Profile
Irinotecan sucrosofate - Ipsen
Alternative Names: BAX-2398; Irinotecan liposome injection - Merrimack; Liposomal irinotecan - Ipsen/Servier; MM-398; nal-IRI; Nano-irinotecan; Nanoliposomal irinotecan - Merrimack/PharmaEngine; Nanoliposomal irinotecan injection - Merrimack/PharmaEngine; Onivyde; pegylated liposomal irinotecan hydrochloride trihydrate; PEP-02; S-095013; SHP-673Latest Information Update: 23 Dec 2024
Price :
$50
*
At a glance
- Originator Academic Medical Center; HERMES BioSciences
- Developer Academic Medical Center; AIO Studien gGmbH; Bristol-Myers Squibb; Emory University; Federation Francophone de Cancerologie Digestive; Ipsen; Medica Scientia Innovation Research; Merrimack Pharmaceuticals; National Cancer Institute (USA); PharmaEngine; Rhode Island Hospital; Servier; Shire; Taiho Pharmaceutical; University of California at San Francisco; University of Florida; University of Michigan
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pancreatic cancer
- Phase III Small cell lung cancer
- Phase II Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; HER2 negative breast cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
- Phase I/II Gastrointestinal cancer; Glioblastoma
- Phase I Solid tumours
- No development reported Glioma
Most Recent Events
- 15 Nov 2024 University of Michigan Rogel Cancer center completes a phase I/II trial in Biliary cancer (Combination therapy, second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT03785873)
- 14 Nov 2024 Servier plans SEOPAC clinical trial for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in November 2024 (IV) (NCT06688240)
- 29 Sep 2024 HERMES BioSciences completes the phase-II OESIRI trial in Oesophageal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in France (IV) (NCT03719924)